Wellstat Therapeutics Corporation – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Wellstat Therapeutics Corporation – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “Wellstat Therapeutics Corporation – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Wellstat Therapeutics Corporation – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Wellstat Therapeutics Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Wellstat Therapeutics Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Wellstat Therapeutics Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Wellstat Therapeutics Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Wellstat Therapeutics Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Wellstat Therapeutics Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Wellstat Therapeutics Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Wellstat Therapeutics Corporation and identify potential opportunities in those areas.
Wellstat Therapeutics Corporation Overview
Key Information
Key Facts
Wellstat Therapeutics Corporation – Research and Development Overview
Key Therapeutic Areas
Wellstat Therapeutics Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Wellstat Therapeutics Corporation – Pipeline Products Glance
Wellstat Therapeutics Corporation – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Wellstat Therapeutics Corporation Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Wellstat Therapeutics Corporation–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Wellstat Therapeutics Corporation – Drug Profiles
PN-401
Product Description
Mechanism of Action
R&D Progress
Vistonuridine + 5-fluorouracil
Product Description
Mechanism of Action
R&D Progress
PN-401
Product Description
Mechanism of Action
R&D Progress
PN2XXX
Product Description
Mechanism of Action
R&D Progress
PN951
Product Description
Mechanism of Action
R&D Progress
PNXXXX
Product Description
Mechanism of Action
R&D Progress
Wellstat Therapeutics Corporation – Pipeline Analysis
Wellstat Therapeutics Corporation – Pipeline Products by Therapeutic Class
Wellstat Therapeutics Corporation Pipeline Products By Target
Wellstat Therapeutics Corporation – Pipeline Products by Route of Administration
Wellstat Therapeutics Corporation – Pipeline Products by Molecule Type
Wellstat Therapeutics Corporation – Locations And Subsidiaries
Head Office
Recent Developments
Financial Deals Landscape
Wellstat Therapeutics Corporation, Deals Summary, 2004 to 2010
Wellstat Therapeutics Corporation Detailed Deal Summary
Licensing Agreements
Wellstat Enters Into License Agreement With Sanofi-Aventis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Wellstat Therapeutics Corporation – Pipeline by Therapy Area and Indication, 2010
Wellstat Therapeutics Corporation – Pipeline by Stage of Development, 2010
Wellstat Therapeutics Corporation – Monotherapy Products in Pipeline, 2010
Wellstat Therapeutics Corporation – Combination Treatment Modalities in Pipeline, 2010
Wellstat Therapeutics Corporation – Filed, 2010
Wellstat Therapeutics Corporation – Phase III, 2010
Wellstat Therapeutics Corporation - Phase I, 2010
Wellstat Therapeutics Corporation - Pipeline By Therapeutic Class, 2010
Wellstat Therapeutics Corporation - Pipeline By Target, 2010
Wellstat Therapeutics Corporation – Pipeline By Route of Administration, 2010
Wellstat Therapeutics Corporation – Pipeline By Molecule Type, 2010
Wellstat Therapeutics Corporation, Deals Summary, 2004 to 2010 28
LIST OF FIGURES
Wellstat Therapeutics Corporation – Pipeline by Therapy Area and Indication, 2010
Wellstat Therapeutics Corporation – Pipeline by Stage of Development, 2010
Wellstat Therapeutics Corporation – Monotherapy Products in Pipeline, 2010
Wellstat Therapeutics Corporation – Combination Treatment Modalities in Pipeline, 2010
Wellstat Therapeutics Corporation – Pipeline By Therapeutic Class, 2010
Wellstat Therapeutics Corporation – Pipeline By Molecule Type, 2010 26
Key Information
Key Facts
Wellstat Therapeutics Corporation – Research and Development Overview
Key Therapeutic Areas
Wellstat Therapeutics Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Wellstat Therapeutics Corporation – Pipeline Products Glance
Wellstat Therapeutics Corporation – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Wellstat Therapeutics Corporation Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Wellstat Therapeutics Corporation–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Wellstat Therapeutics Corporation – Drug Profiles
PN-401
Product Description
Mechanism of Action
R&D Progress
Vistonuridine + 5-fluorouracil
Product Description
Mechanism of Action
R&D Progress
PN-401
Product Description
Mechanism of Action
R&D Progress
PN2XXX
Product Description
Mechanism of Action
R&D Progress
PN951
Product Description
Mechanism of Action
R&D Progress
PNXXXX
Product Description
Mechanism of Action
R&D Progress
Wellstat Therapeutics Corporation – Pipeline Analysis
Wellstat Therapeutics Corporation – Pipeline Products by Therapeutic Class
Wellstat Therapeutics Corporation Pipeline Products By Target
Wellstat Therapeutics Corporation – Pipeline Products by Route of Administration
Wellstat Therapeutics Corporation – Pipeline Products by Molecule Type
Wellstat Therapeutics Corporation – Locations And Subsidiaries
Head Office
Recent Developments
Financial Deals Landscape
Wellstat Therapeutics Corporation, Deals Summary, 2004 to 2010
Wellstat Therapeutics Corporation Detailed Deal Summary
Licensing Agreements
Wellstat Enters Into License Agreement With Sanofi-Aventis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Wellstat Therapeutics Corporation – Pipeline by Therapy Area and Indication, 2010
Wellstat Therapeutics Corporation – Pipeline by Stage of Development, 2010
Wellstat Therapeutics Corporation – Monotherapy Products in Pipeline, 2010
Wellstat Therapeutics Corporation – Combination Treatment Modalities in Pipeline, 2010
Wellstat Therapeutics Corporation – Filed, 2010
Wellstat Therapeutics Corporation – Phase III, 2010
Wellstat Therapeutics Corporation - Phase I, 2010
Wellstat Therapeutics Corporation - Pipeline By Therapeutic Class, 2010
Wellstat Therapeutics Corporation - Pipeline By Target, 2010
Wellstat Therapeutics Corporation – Pipeline By Route of Administration, 2010
Wellstat Therapeutics Corporation – Pipeline By Molecule Type, 2010
Wellstat Therapeutics Corporation, Deals Summary, 2004 to 2010 28
LIST OF FIGURES
Wellstat Therapeutics Corporation – Pipeline by Therapy Area and Indication, 2010
Wellstat Therapeutics Corporation – Pipeline by Stage of Development, 2010
Wellstat Therapeutics Corporation – Monotherapy Products in Pipeline, 2010
Wellstat Therapeutics Corporation – Combination Treatment Modalities in Pipeline, 2010
Wellstat Therapeutics Corporation – Pipeline By Therapeutic Class, 2010
Wellstat Therapeutics Corporation – Pipeline By Molecule Type, 2010 26